Brassinosteroids cause cell cycle arrest and apoptosis of human breast cancer cells

Chemico-Biological Interactions

Volumn 188, Issue 3, 2010, Pages 487-496

  Steigerová, Jana ^a   Oklestkova, Jana ^b   Levková, Monika ^a   Rárová, Lucie ^b   Kolář, Zdeněk ^a   Strnad, Miroslav ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

Apoptosis; Brassinosteroids; Cell cycle; Hormone sensitive insensitive breast cancer cells

Indexed keywords

24 EPIBRASSINOLIDE; 28 HOMOCASTASTERONE; ACRIDINE ORANGE; BRASSINOSTEROID; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; MITOSIS INHIBITION; NICK END LABELING; PROTEIN LOCALIZATION; WESTERN BLOTTING;

EMBRYOPHYTA;

EID: 78149497581     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.09.006     Document Type: Article

References (56)

1. Bray F., McCarron P., Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004, 6:229-239.
2. Wang L.H., Yang X.Y., Zhang X., An P., Kim H.J., Huang J., Clarke R., Osborne C.K., Inman J.K., Appella E., Farrar W.L. Disruption of estrogen receptor DNA binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006, 10:487-499.
3. Ascenzi P., Bocedi A., Marino M. Structure-function relationship of estrogen receptor α and β: impact on human health. Mol. Aspects Med. 2006, 27:299-402.
4. Mosselman S., Polman J., Dijkema R. ER-β: identification and characterisation of a novel human oestrogen receptor. FEBS Lett. 1996, 392:49-53.
5. Osborne C.K., Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 2005, 23:1616-1622.
6. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C., Katzenellenbogen J.A., Korach K.S., Maggi A., Muramatsu M., Parker M.G., Gustafsson J.A. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 2006, 58:773-781.
7. 1 gene expression. J. Biol. Chem. 2002, 277:24353-24360.
8. Holst F., Stahl P.R., Ruiz C., Hellwinkel O., Jehan Z., Wendland M., Lebeau A., Terracciano L., Al-Kuraya K., Jänicke F., Sauter G., Simon R. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 2007, 39:655-660.
9. Jordan V.C. SERMs: meeting the promise of multifunctional medicines. J. Natl. Cancer Inst. 2007, 99:350-356.
10. Giacinti L., Claudio P.P., Lopez M., Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11:1-8.
11. Hail N., Lotan R. Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J. Natl. Cancer Inst. 2002, 94:1281-1292.
12. Newman D.J., Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr. Med. Chem. 2004, 11:1693-1713.
13. Veselý J., Havlíček L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., Leclerc S., et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224:771-786.
14. De Azevedo W.F., Leclerc S., Meijer L., Havlíček L., Strnad M., Kim S.H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243:518-526.
15. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1:222-231.
16. Bajguz A., Tretyn A. The chemical characteristic and distribution of brassinosteroids in plants. Phytochemistry 2003, 62:1027-1046.
17. Khripach V.A., Zhabinski V., de A.E., Groot A New Class of Plant Hormones 1999, Academic Press, San Diego, p. 456.
18. Clouse S.D. Brassinosteroid signaling: novel downstream components emerge. Curr. Biol. 2002, 12:R485-487.
19. Malíková J., Swaczynová J., Kolář Z., Strnad M. Anticancer and antiproliferative activity of natural brassinosteroids. Phytochemistry 2008, 69:418-426.
20. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5:231-237.
21. Nicolaou K.C., Boddy C.N. Behind enemy lines. Sci. Am. 2001, 284:54-61.
22. Van Doorn W.G., Woltering E.J. Many ways to exit? Cell death categories in plants. Trends Plant Sci. 2005, 10:117-122.
23. van den Heuvel S., Dyson N.J. Conserved functions of the pRb and E2F families. Nat. Rev. Mol. Cell Biol. 2008, 9:713-724.
24. Macaluso M., Montanari M., Giordano A. The regulation of ER-alpha transcription by pRb2/p130 in breast cancer. Ann. Oncol. 2005, 16(Suppl. 2):20-22.
25. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
26. Somaï S., Chaouat M., Jacob D., Perrot J.Y., Rostène W., Forgez P., Gompel A. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int. J. Cancer 2003, 105:607-612.
27. Jamerson M.H., Johnson M.D., Dickson R.B. Of mice and Myc: c-Myc and mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 2004, 9:27-37.
28. Pledgie-Tracy A., Sobolewski M.D., Davidson N.E. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther. 2007, 6:1013-1021.
29. Journe F., Chaboteaux C., Magne N., Duvillier H., Laurent G., Body J.J. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006, 8:R2.
30. Doisneau-Sixou S.F., Sergio C.M., Carroll J.S., Hui R., Musgrove E.A., Sutherland R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 2003, 10:179-186.
31. Caldon C.E., Daly R.J., Sutherland R.L., Musgrove E.A. Cell cycle control in breast cancer cells. J. Cell Biochem. 2006, 97:261-274.
32. Macri E., Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998, 17:337-344.
33. Prall O.W., Carroll J.S., Sutherland R.L. A low abundance pool of nascent p21WAF/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. J. Biol. Chem. 2001, 276:45433-45442.
34. 1 cyclin-dependent kinases. Genes Dev. 1995, 9:1149-1163.
35. Muraoka R.S., Lenferink A.E., Simpson J., Brantley D.M., Roebuck L.R., Yakes F.M., Arteaga C.L. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J. Cell Biol. 2001, 153:917-932.
36. Mo H.B., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 2004, 229:567-585.
37. Fukuoka K., Yamagishi T., Ichihara T., Nakaike S., Iguchi K., Yamada Y., Fukumoto H., Yoneda T., Samata K., Ikeya H., Nanaumi K., Hirayama N., Narita N., Saijo N., Nishio K. Mechanism of action of aragusterol a (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle. Int. J. Cancer 2000, 88:810-819.
38. Watts C.K., Brady A., Sarcevic B., deFazio A., Musgrove E.A., Sutherland R.L. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 1995, 9:1804-1813.
39. Carroll J.S., Lynch D.K., Swabrick A., Renoir J.M., Sarcevic B., Daly R.J., Musgrove E.A., Sutherland R.L. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res. 2003, 63:4322-4326.
40. Sayeed A., Konduri S.D., Liu W., Bansal S., Li F., Das G.M. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007, 67:7746-7755.
41. Duong V., Boulle N., Daujat S., Chauvet J., Bonnet S., Neel H., Cavaillès V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 2007, 67:5513-5521.
42. Mandlekar S., Yu R., Tan T.H., Kong A.N. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 2000, 60:5995-6000.
43. Thiantanawat A., Long B.J., Brodie A.M. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 2003, 63:8037-8050.
44. Gompel A., Somaï S., Chaouat M., Kazem A., Kloosterboer H.J., Beusman I., Forgez P., Mimoun M., Rostène W. Hormonal regulation of apoptosis in breast cancer cells and tissues. Steroids 2000, 65:593-598.
45. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
46. Chinnaiyan A.M., Orth K., O'Rourke K., Duan H., Poirier G.G., Dixit V.M. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J. Biol. Chem. 1996, 271:4573-4576.
47. Jänicke R.U., Sprengart M.L., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998, 273:9357-9360.
48. Ameller T., Marsaud V., Legrand P., Gref R., Renoir J.M. In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carries loaded with the pure antiestrogen RU 58668. Int. J. Cancer 2003, 106:446-454.
49. Hur J., Chesnes J., Coser K.R., Lee R.S., Geck P., Isselbacher K.J., Shioda T. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2351-2356.
50. Frasor J., Chang E.C., Komm B., Lin C.Y., Vega V.B., Liu E.T., Miller L.D., Smeds J., Bergh J., Katzenellenbogen B.S. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006, 66:7334-7340.
51. Sabbah M., Courilleau D., Mester J., Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11217-11222.
52. Micheau O., Solary E., Hammann A., Dimanche-Boitrel M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 1999, 274:7987-7992.
53. Eilon G., Mundy G.R. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978, 276:726-728.
54. Parl F.F. Estrogens, Estrogen Receptor and Breast Cancer 2000, 36:272. IOS Press, Amsterdam.
55. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996, 56:2973-2978.
56. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.